News ArticleStrides Pharma Science Limited Announces Unaudited Consolidated and Standalone Financial Results for Q2 and H1 FY2027
Board approved financial performance includes data from multiple subsidiaries and associates, with independent review by B S R & Co. LLP completed on October 29, 2026
Strides Pharma Science Limited announced its unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026. The results, approved by the Board of Directors on October 29, 2026, include data from subsidiaries and associates, and the review was conducted by B S R & Co. LLP. The report covers total assets, revenues, net profits and losses, and cash flows across various entities in the group.
Strides Pharma Science Limited
Financial Results
Strides Pharma Science Limited released its unaudited financial results for the quarter and half year ended September 30, 2026, reflecting consolidated and standalone performance across its subsidiaries and associates. The results were reviewed by independent auditors B S R & Co. LLP and approved by the Board on October 29, 2026.
The quarterly and half-year financial statements include consolidated data from 28 subsidiaries, associates, and a joint venture, showing combined total assets, revenue, net profit or loss, and cash flows as reported by these entities before consolidation adjustments.
The review was performed in accordance with Indian Accounting Standard 34 (Interim Financial Reporting) and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with applicable accounting principles and regulatory requirements.
Certain subsidiaries’ interim financial information was reviewed by other auditors, while some subsidiaries and associates' financials included in the consolidation were not reviewed but are considered immaterial to the overall group.
Key audited figures include total assets of selected subsidiaries amounting to Rs. 6,861 million and revenues of Rs. 2,224 million for the quarter, alongside other financial indicators and comprehensive income data.
The unaudited results and the auditors’ limited review report have been made publicly available on the company’s website for investor review and regulatory transparency.
Highlights
- Unaudited consolidated and standalone financial results released for Q2 and H1 ended September 30, 2026.
- Board meeting held on October 29, 2026, with approval of results between 16:45 and 18:15 IST.
- Review conducted by B S R & Co. LLP as per Indian Accounting Standard 34 and SEBI regulations.
- Results include data from 28 subsidiaries, associates, and a joint venture, with some unaudited financial information.
- Total assets before consolidation adjustments for key subsidiaries at Rs. 6,861 million for the quarter.
- Revenue before consolidation adjustments for key subsidiaries at Rs. 2,224 million for the quarter, Rs. 4,414 million for H1 FY2027.
Key Data Snapshot
What happened
- Strides Pharma Science Limited announced unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026.
- The Board of Directors approved the results at the meeting held on October 29, 2026, from 16:45 to 18:15 IST.
- Results include financial data from 28 subsidiaries, associates, and a joint venture within the consolidated group.
Key details
- Total assets before consolidation adjustments of reviewed subsidiaries amounted to Rs. 6,861 million as at September 30, 2026.
- Total revenues before consolidation adjustments for these subsidiaries were Rs. 2,224 million for the quarter and Rs. 4,414 million for the half year.
- Net profit after tax of these subsidiaries stood at Rs. 76 million for the quarter and Rs. 429 million for the half year.
- Unreviewed subsidiaries collectively had total assets amounting to Rs. 49,386 million and reported revenues of Rs. 1,668 million for the quarter and Rs. 3,661 million for the half year.
- Net losses after tax of unreviewed subsidiaries were Rs. 244 million for the quarter and Rs. 172 million for the half year.
Regulatory and governance context
- The financial results were prepared following Indian Accounting Standard 34 (Interim Financial Reporting) and comply with SEBI Listing Regulations.
- Independent review was performed by B S R & Co. LLP as per Standard on Review Engagements 2410.
- Certain subsidiaries’ interim financial statements were reviewed by other auditors; others were not reviewed due to materiality considerations.
- The group's management is responsible for preparation and approval of the statement.
- The results and audit reports have been made available on the company website for compliance and investor access.
Highlights
- Unaudited consolidated and standalone financial results released for Q2 and H1 ended September 30, 2026.
- Board meeting held on October 29, 2026, with approval of results between 16:45 and 18:15 IST.
- Review conducted by B S R & Co. LLP as per Indian Accounting Standard 34 and SEBI regulations.
- Results include data from 28 subsidiaries, associates, and a joint venture, with some unaudited financial information.
- Total assets before consolidation adjustments for key subsidiaries at Rs. 6,861 million for the quarter.
- Revenue before consolidation adjustments for key subsidiaries at Rs. 2,224 million for the quarter, Rs. 4,414 million for H1 FY2027.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 'Interim Financial Reporting'
- Standard on Review Engagements (SRE) 2410
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Indegene Limited Announces Unaudited Consolidated and Standalone Results for Q2 and H1 Ending September 30, 2026
Indegene Limited approved its unaudited consolidated and standalone financial results for the second quarter and half year ended September 30, 2026, alongside approving allotments under RSU and ESOP schemes and key personnel resignations during its board meeting on October 29, 2026.
Read Full Story
Alivus Life Sciences Posts ₹3,568 Million Net Profit in First Half of FY2026, Q2 Net Profit at ₹1,967 Million
Alivus Life Sciences Limited has reported its unaudited financial results for the second quarter and half year ended September 30, 2026, posting a net profit of ₹1,967 million for the quarter and ₹3,568 million for the half year, supported by revenue growth.
Read Full Story
Timken India Limited Achieves Rs 2,311.94 Million Net Profit for First Half of FY 2026-27
Timken India Limited reported a net profit after tax of Rs 2,311.94 million for the half year ended September 30, 2026, with revenue from operations totaling Rs 18,983.82 million, as per its unaudited standalone financial results approved by the Board on October 29, 2026.
Read Full Story
